1 Year, Open-label Multicenter Evaluation of Efficacy, Safety of Deferasirox in Patients MDS, Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
changes in ferritin level, compared to baseline, in patients with transfusion-induced iron overload treated with Exjade
Baseline assessment is followed by monthly assessments for up to 1 year
Russia: Ministry of Health